Tag Archives: EGFR

Chi-Med, AstraZeneca’s savolitinib helps some Tagrisso-resistant EGFR lung cancer patients

ATLANTA—AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med. The Chinese company Sunday rolled out phase 1b results showing that certain treatment-resistant patients showed improvement after receiving a combination of Tagrisso, which targets the EGFR gene mutation, and Chi-Med’s savolitinib, a MET inhibitor… Read More »